BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kadelka S, Dahari H, Ciupe SM. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci Rep 2021;11:200. [PMID: 33420293 DOI: 10.1038/s41598-020-80594-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines (Basel) 2021;9:359. [PMID: 33918072 DOI: 10.3390/vaccines9040359] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
2 Wang R, Xie Z. A Simple and Rapid Method for Quantitative Detection of Hepatitis B Virus Drug-resistant Mutations. J Clin Transl Hepatol 2021;9:139-40. [PMID: 34007793 DOI: 10.14218/JCTH.2021.00135] [Reference Citation Analysis]
3 Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. J Virol 2021;95:e0049220. [PMID: 33910953 DOI: 10.1128/JVI.00492-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
5 Magadán S, Mikelez-Alonso I, Borrego F, González-Fernández Á. Nanoparticles and trained immunity: Glimpse into the future. Adv Drug Deliv Rev 2021;175:113821. [PMID: 34087325 DOI: 10.1016/j.addr.2021.05.031] [Reference Citation Analysis]